Cannabinoid therapeutics developer Zynerba Pharmaceuticals (ZYNE+37.5%) is up on more than a 7x surge in volume in early trade as shares break out from near-term consolidation.
Topline data from its Phase 2/3 CONNECT-FX study evaluating ZYN002, a cannabinoid transdermal gel, in patients with Fragile X syndrome should be available in H2 (corp. presentation, slide #4).
On the working capital front, at the end of September 2018, it had $66.2M in cash and equivalents while operations consumed $26.2M during the first three quarters of the year.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.